A Study of the Effectiveness of Rifaprim in Chronic prostatitis Caused Mainly by Staphylococcus Aureus
1982; Lippincott Williams & Wilkins; Volume: 128; Issue: 2 Linguagem: Inglês
10.1016/s0022-5347(17)52906-7
ISSN1527-3792
AutoresHelen Giamarellou, J. Kosmidis, Mvuyekure Leonidas, Michalis Papadakis, G. K. Daikos,
Tópico(s)Urinary Tract Infections Management
ResumoRifampicin plus trimethoprim (rifaprim) was used to treat 20 patients with chronic prostatitis in exacerbation: 11 received 2 tablets at bedtime for 15 days followed by 1 tablet at bedtime for another 105 days, and 9 received 1 tablet in the morning and 2 tablets at bedtime for 15 days, then 2 tablets at bedtime for 15 days followed by 1 tablet at bedtime for another 90 days. All patients had an enlarged tender prostate and all but 2 were symptomatic. In 10 patients previous treatment, including co-trimoxazole in 5, had failed. Cultures of the expressed prostatic secretions yielded Staphylococcus aureus in 17 patients and gram-negative micro-organisms in 3. At the end of treatment 6 of 11 patients given the lower dosage were cured clinically and bacteriologically compared to 8 of 9 given the higher dosage. After 2 to 3 years of following 5 of 9 patients in the first group and all 7 in the second group had not suffered relapse. From our study it is evident that rifaprim is a potent drug in the treatment of chronic prostatitis caused mainly by Staphylococcus aureus. A promptness of therapeutic response and the rate of cure at the end of treatment as well as after at least 2 years of followup favor the higher drug dosage.
Referência(s)